Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 53.6% in August

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 3,900 shares, a decrease of 53.6% from the August 15th total of 8,400 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 43,700 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ACHL. Vestal Point Capital LP bought a new position in shares of Achilles Therapeutics during the fourth quarter worth approximately $96,000. Acadian Asset Management LLC bought a new position in shares of Achilles Therapeutics during the first quarter worth approximately $350,000. StemPoint Capital LP bought a new position in shares of Achilles Therapeutics during the first quarter worth approximately $1,732,000. Ikarian Capital LLC bought a new position in shares of Achilles Therapeutics during the first quarter worth approximately $1,804,000. Finally, XTX Topco Ltd increased its holdings in shares of Achilles Therapeutics by 239.4% during the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after purchasing an additional 36,441 shares during the period. 56.38% of the stock is owned by institutional investors.

Achilles Therapeutics Stock Performance

Shares of NASDAQ:ACHL opened at $0.72 on Friday. Achilles Therapeutics has a 52-week low of $0.63 and a 52-week high of $1.76. The company has a market capitalization of $29.70 million, a P/E ratio of -0.45 and a beta of 1.31. The company has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $0.91.

Achilles Therapeutics (NASDAQ:ACHL) last issued its earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.41). As a group, equities analysts forecast that Achilles Therapeutics will post -1.19 earnings per share for the current year.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.